Skip to main content
SpringerLink
Log in

Treatment of Advanced Renal Cell Carcinoma by Systemic Low-Dose Recombinant Interleukin-2

  • Conference paper
Immunotherapy of Renal Cell Carcinoma

Abstract

In 1976, Morgan and his associates [1] first reported that interleukin-2 (IL-2) was a T-cell growth factor. Since then, various biological activities of IL-2 [2] have been elucidated, including proliferation of T cells, natural killer (NK) cells, and lymphokine-activated killer (LAK) cells; induction of cytotoxicity of killer T cells, NK cells, LAK cells, and monocytes; induction of lymphokine production such as interferon, EL-3, -4, -5, -6, colony stimulating factor, and tumor necrosis factor; and induction of receptors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Morgan PA, Ruscetti FW, Gallo R (1976) Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193: 1007–1008

    Article  PubMed  CAS  Google Scholar 

  2. Oliver RTD (1988) The clinical potential of interleukin-2. Br J Cancer 58: 405–409

    Article  PubMed  CAS  Google Scholar 

  3. Rosenberg SA, Lotze MT, Muul LM et al. (1985) Observation on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313: 1485–1492

    Article  PubMed  CAS  Google Scholar 

  4. Rosenberg SA, Lotze T, Mule JJ (1988) New approaches to the immunotherapy of cancer using interleukin-2. Ann Int Med 108: 853–864

    PubMed  CAS  Google Scholar 

  5. Parkinson DR (1988) Interleukin-2 in cancer therapy. Seminars in Oncology 15 (Suppl 6): 10–26

    PubMed  CAS  Google Scholar 

  6. Rosenberg SA, Lotze MT, Muul LM et al. (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Eng J Med 316: 889–897

    Article  CAS  Google Scholar 

  7. Fisher RI, Coltman CA, Doroshow JH et al. (1988) Metastatic renal cell cancer treated with interleukin-2 and lymphokine-activated killer cells. Ann Int Med 108: 518–523

    PubMed  CAS  Google Scholar 

  8. Lotze MT, Chang AE, Seipp CA etal. (1986) High dose recombinant inter- leukin-2 in the treatment of patients with disseminated cancer: Responses, treatment related morbidity, and histologic findings. JAMA 256: 3117–3124

    Google Scholar 

  9. Van Haelst-Pisani CM, Pisani R, Kovach JS (1989) Cancer immunotherapy: Current status of treatment with interleukin-2 and lymphokine-activated killer cells. Mayo Clin Proc 64: 451–465

    PubMed  Google Scholar 

  10. Sosman JA, Köhler PC, Hank J etal. (1988) Repetitive weekly cycles of recombinant human interleukin-2: Responses of renal carcinoma with acceptable toxicity. J Natl Cancer Inst 80: 60–64

    Article  PubMed  CAS  Google Scholar 

  11. Sondel PM, Köhler PC, Hank JA etal. (1988) Recombinant interleukin-2 given by repetitive weekly cycles in patients with cancer: Clinical and immunologic effects. Cancer Res 48: 2561–2567

    PubMed  CAS  Google Scholar 

  12. Sosman JA, Kohler PC, Hank JA etal. (1988) Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin. J Natl Cancer Inst 80: 1451–1461

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, The University of Tokyo, 7-3-1 Hongo, 113, Bunkyo-ku, Tokyo, Japan

    Y. Aso & T. Umeda

  2. Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, 113, Bunkyo-ku, Tokyo, Japan

    Y. Aso & T. Umeda

  3. Department of Urology, Keio University Medical School, 160, Shinano-machi, Tokyo, Japan

    H. Tazaki & K. Marumo

Authors
  1. Y. Aso
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Tazaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Umeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. Marumo
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Urology, University Hospital Nijmegen, P. O. Box 9101, 6500 HB, Nijmegen, The Netherlands

    Frans M. J. Debruyne MD, Ph.D. (Director Chairman) (Director Chairman)

  2. Cleveland Clinic Cancer Center, Cleveland Clinic Foundation, 9500 Euclid Avenue, 44106, Cleveland, Ohio, USA

    Ronald M. Bukowski MD (Director, Clinical Research) (Director, Clinical Research)

  3. Department of Urology, Wayne State University, 4160 John R., Suite 1017, 48201, Detroit, Michigan, USA

    J. Edson Pontes MD, Ph.D. (Professor and Chairman) (Professor and Chairman)

  4. Department of Medical Oncology, University Hospital Nijmegen, P. O. Box 9101, 6500 HB, Nijmegen, The Netherlands

    Pieter H. M. de Mulder MD, Ph.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Aso, Y., Tazaki, H., Umeda, T., Marumo, K. (1991). Treatment of Advanced Renal Cell Carcinoma by Systemic Low-Dose Recombinant Interleukin-2. In: Debruyne, F.M.J., Bukowski, R.M., Pontes, J.E., de Mulder, P.H.M. (eds) Immunotherapy of Renal Cell Carcinoma. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-75853-9_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-75853-9_14

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-52835-7

  • Online ISBN: 978-3-642-75853-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation